OASYS NOW launches GRIP: aims to revolutionise treatment discovery for chronic and rare diseases

|

|

Last update:

Delft-based OASYS NOW, a company that offers patient-centric Clinical Trial technology solutions and healthcare data management, announced the launch of its new platform, GRIP, which gives citizens control and insight into their health and patient journey.

This tool aims to simplify the trial matching process, boost patient engagement, and expedite medical research.

Nima Salami, CEO and co-founder of OASYS NOW says, “Like many chronic disease patients, my mother, unaware of when – if ever – curative treatment options would become available for her, perceived her health condition as something she had to carry through for the rest of her life.” 

“Knowing the ever-increasing rate of new medicine developments, I couldn’t accept the fact that lack of appropriate technical solutions in the data and information age, would be the reason for her feeling lost while navigating her health journey.”

“So, together with our multidisciplinary team, we set out to build a patient-centric personalised health platform that addresses the current shortcomings of digital systems in healthcare, and, complementarily, enables more equitable and globally collaborative clinical research,” adds Salami.

Brief about GRIP

The GRIP platform, developed by OASYS NOW in collaboration with major healthcare institutions, addresses the challenges faced by patients diagnosed with rare or chronic conditions. 

Often overwhelmed by the initial diagnosis and lack of available treatments, patients can now use GRIP as a digital waiting room. This platform empowers individuals by providing access to up-to-date information on promising new medicines and clinical trials related to their conditions. 

By taking control of their electronic health records, patients can stay informed about the latest developments in the clinical field, bridging the gap between medical advancements and the patient’s journey.

OASYS NOW also aims to streamline the eligibility assessment process for drug development companies by leveraging digital technologies. GRIP aims to reduce the need for multiple in-person visits by enabling the remote collection of electronic health records (EHR) through its GRIP technology.

This technology automates the comparison between patients’ health records and the specific eligibility criteria of each clinical study, streamlining the assessment process. Overall, OASYS NOW seeks to expedite and simplify the evaluation of whether new medicines are suitable for individual patients in the context of clinical trials.

GRIP also tackles the substantial delays in trial recruitment. It streamlines the trial search, enhancing the alignment between patient profiles and research studies to address this challenge in the recruitment process.

Looking to raise Seed funding

On December 1, OASYS NOW is unveiling GRIP at the Slush Conference in Helsinki, where they’re a top 100 finalist in a competition with major funds offering €1B to the best startup.

As of today, GRIP is accessible to the public at www.oasysnow.com. This launch signals the commencement of the Seed round of fundraising for OASYS NOW, with a target of €2M-€3M.

The funds will be utilised to enhance their platforms, extend services to additional European countries, and advance data processing tools aimed at improving insights extraction from Electronic Health Records (EHR).

Topics:

Follow us:

Vishal Singh

Vishal Singh is a News Reporter and Social Media Marketing Lead at Silicon Canals. He covers developments in the European startup ecosystem and oversees the publication's social media presence. Before joining Silicon Canals, Vishal gained experience at the Indian digital media outlet Inc42, contributing to its growth with insightful content. Despite being a college dropout, his passion for writing has driven his career in journalism.

Partner eventsMore events

Current Month

28jan4:00 pm10:00 pmUnlocking operational efficiency with AIInsights for your future

Share to...